| Literature DB >> 27977670 |
Koussay Dellagi1,2, Nicolas Salez3, Marianne Maquart4, Sophie Larrieu5, Amina Yssouf6, Rahamatou Silaï6, Isabelle Leparc-Goffart4, Pablo Tortosa1,2, Xavier de Lamballerie3.
Abstract
A cross sectional serological survey of arboviral infections in humans was conducted on the three islands of the Union of Comoros, Indian Ocean, in order to test a previously suggested contrasted exposure of the three neighboring islands to arthropod-borne epidemics. Four hundred human sera were collected on Ngazidja (Grande Comore), Mwali (Mohéli) and Ndzouani (Anjouan), and were tested by ELISA for IgM and/or IgG antibodies to Dengue (DENV), Chikungunya (CHIKV), Rift Valley fever (RVFV), West Nile (WNV), Tick borne encephalitis (TBEV) and Yellow fever (YFV) viruses and for neutralizing antibodies to DENV serotypes 1-4. Very few sera were positive for IgM antibodies to the tested viruses indicating that the sero-survey was performed during an inter epidemic phase for the investigated arbovirus infections, except for RVF which showed evidence of recent infections on all three islands. IgG reactivity with at least one arbovirus was observed in almost 85% of tested sera, with seropositivity rates increasing with age, indicative of an intense and long lasting exposure of the Comorian population to arboviral risk. Interestingly, the positivity rates for IgG antibodies to DENV and CHIKV were significantly higher on Ngazidja, confirming the previously suggested prominent exposure of this island to these arboviruses, while serological traces of WNV infection were detected most frequently on Mwali suggesting some transmission specificities associated with this island only. The study provides the first evidence for circulation of RVFV in human populations from the Union of Comoros and further suggests that the virus is currently circulating on the three islands in an inconspicuous manner. This study supports contrasted exposure of the islands of the Comoros archipelago to arboviral infections. The observation is discussed in terms of ecological factors that may affect the abundance and distribution of vector populations on the three islands as well as concurring anthropogenic factors that may impact arbovirus transmission in this diverse island ecosystem.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27977670 PMCID: PMC5157944 DOI: 10.1371/journal.pntd.0004840
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Distribution of the study sample according to gender, age class and island.
| <15yo | 15-30yo | 31-50yo | >50yo | All age classes | |
|---|---|---|---|---|---|
| Ngazidja | 41 | 52 | 59 | 44 | 196 |
| Females, Males | 23, 18 | 32, 20 | 36, 23 | 25, 19 | 116, 80 |
| Mwali | 4 | 42 | 51 | 19 | 116 |
| Females, Males | 3, 1 | 34, 8 | 30, 21 | 8, 11 | 75, 41 |
| Ndzouani | 22 | 39 | 21 | 6 | 88 |
| Females, Males | 9, 13 | 31, 8 | 15, 6 | 3, 3 | 58, 30 |
| Total | 62 | 133 | 131 | 74 | 400 |
IgG antibodies to each arbovirus according to living Island and to the status of serum donors (n = 400).
The positivity criteria is a Absorbance Ratio to the cut-off value >1.1.
| Ngazidja n = 196 | Mwali n = 116 | Ndzouani n = 88 | Total n = 400 | Healthy group n = 75 | Unhealthy group n = 325 | |||
|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |||
| CHIKV | 37 (18.9) | 9 (7.8) | 2 (2.3) | 48 (12.0) | <0.0001 | 12 (16.0) | 36 (11.0) | 0.24 |
| RVFV | 31 (15.8) | 6 (5.2) | 6 (6.8) | 43 (10.7) | 0.005 | 17 (22.7) | 26 (8.0) | <0.001 |
| DENV | 174 (88.8) | 77 (66.4) | 49 (55.7) | 300 (75.0) | <0.0001 | 54 72.0) | 235 (72.3) | 0.96 |
| TBEV | 3 (1.5) | 0 (0.0) | 0 (0.0) | 3 (0.7) | 0.20 | 3 (4.0) | 0 (0.0) | <0.01 |
| YFV | 2 (1.0) | 0 (0.0) | 0 (0.0) | 2 (0.5) | 0.35 | 0 (0.0) | 2 (0.6) | 0.96 |
| WNV | 6 (3.1) | 21 (18.1) | 2 (2.3) | 29 (7.3) | <0.0001 | 6 (8.0) | 14 (4.3) | 0.19 |
IgM antibodies to DENV, WNV, CHIKV and RVFV in 364 sera collected from Grande Comore, Moheli and Anjouan.
| Ngazidja n positive /n tested (prevalence in the sample) | Mwali n positive /n tested (prevalence in the sample) | Ndzouani n positive /n tested (prevalence in the sample) | Total (prevalence in the sample) | |
|---|---|---|---|---|
| DENV | 2/ 160 (1,25%) | 1/117 (0.85%) | 0/87 (0%) | 3/364 (0.82%) |
| WNV | 0/160 (0%) | 2/117 (1.70%) | 0/87 (0%) | 2/ 364 (0.55%) |
| CHIKV | 0/160 (0%) | 0/117 (0%) | 0/87 (0%) | 0/ 364 (0%) |
| RVFV | 4/160 (2.5%) | 12/117 (10.25%) | 7/87 (8.04%) | 23/ 364 (6.31%) |
Number of sera with neutralizing antibodies to DENV serotypes 1–4 according to (i) the neutralized serotype(s), (ii) the dominant serotype, (iii) the Island and (iv) the age class.
Presented data concern a subset of 90 randomly selected DENV ELISA positive samples. (* Numbers may not add up as one individual serum may react with more than one serotype).
| DENV Serotype | Serotype | Serotype | Serotype | Serotype |
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| i) Number* of sera with neutralizing antibodies to the indicated DENV serotype: | 57 (63.3%) | 47 (52.2%) | 68 (75.6%) | 44 (48.9%) |
| ii) Number* of sera with neutralizing antibodies to the indicated serotype considered as dominant serotype: | 35 (38.9%) | 21 (23.3%) | 31 (34.4%) | 14 (15.6%) |
| iii) Island: | ||||
| Grande Comore (Ngazidja) | 25 | 15 | 25 | 7 |
| Moheli (Mwali) | 8 | 4 | 4 | 6 |
| Anjouan (Ndzouani) | 2 | 2 | 2 | 1 |
| iv) Age class: | ||||
| <15yo | 8 | 6 | 16 | 1 |
| 15-30yo | 12 | 4 | 8 | 4 |
| 30-50yo | 15 | 11 | 7 | 9 |
Neutralizing antibodies for DENV serotypes 1–4.
Reactivity profile according to the number of seroneutralized serotypes detected in 78 out of 90 randomly selected DENV ELISA positive samples.
| Island of origin and age class | Grande Comore (Ngazidja) | Moheli (Mwali) | Anjouan (Ndzouani) | Total tested | <15yo | 15-30yo | 30-50yo |
|---|---|---|---|---|---|---|---|
| Number of sera with neutralizing antibodies to DENV serotypes 1–4 | 54 | 18 | 6 | 78 | 23 | 22 | 33 |
| Number of sera with neutralizing antibodies to DENV according to the number of reactive serotypes | |||||||
| 1 serotype | 5 (9.2%) | 6 (33.3%) | 3 (50.0%) | 14 | 4 (17.4%) | 6 (27.3%) | 4 (12.1%) |
| 2 serotypes | 17 (31.5%) | 5 (27.8%) | 0 (0.0%) | 22 | 10 (43.5%) | 7 (31.8%) | 5 (15.1%) |
| 3 serotypes | 12 (22.2%) | 3 (16.7%) | 1 (16.6%) | 16 | 6 (26.1%) | 2 (9.1%) | 8 (22.2%) |
| 4 serotypes | 20 (37.0%) | 4 (22.2%) | 2 (33.2%) | 26 | 3 (13.0%) | 7 (31.8%) | 16 (48.5%) |